Collaborative research efforts have seen a novel monoclonal antibody, suvratoxumab, complete a Phase II trial targeted towards Staphylococcus aureus. This SAATELLITE study comes as the first clinical trial in the Innovative Medicines Initiative, formed to develop alternative medicines to combat antibiotic resistance.
New research describes the use of small-molecule CD4 mimetic compounds that force HIV to undergo conformational changes, exposing normally hidden parts of the envelope and potential new targets.
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.
Vaccination during pregnancy provides important benefits, so why are pregnant women excluded from clinical trials? Learn more about the path towards including this group in vaccine development for both routine and emergency vaccinations.
Take a look behind the scenes of a recent Future Virology review, entitled: ‘TRIM proteins: an emerging antiviral protein family’, as we ask the authors about TRIM proteins, viral resistance and the future of this field.
Take a look at this month’s industry headlines including Priority Review for two antibacterial agents from Merck (NJ, USA), a clinical trial for a new malaria drug and the launch of omadacycline in the USA.
Take a look behind the scenes of a recent Future Microbiology review as we ask the authors about quorum quenching and using nanoparticles as antibiotics.
New research has developed a nanoparticle formulation that can knock down a key chlamydia binding protein and simultaneously induce autophagy – showing promise against this infection.
Some of the challenges with mass ivermectin administration could be addressed with new drugs or drug combinations with higher effect for the parasite – leading us to ask, what new treatments are currently in the clinical pipeline?
